Comparative effects of premarin, evista, and placebo on sleep architecture, sleep quality, and hot flush frequency in postmenopausal women

Abstract Introduction Children with achondroplasia and Trisomy 21 (T21) have increased incidence of sleep disturbances including sleep disordered breathing. Abnormal sleep architecture has been documented in children with T21. It is important to continue to analyze sleep parameters in both groups since poor sleep quality is associated with neurocognitive impairment. Methods Following IRB approval, we performed a retrospective chart review of patients at Nemours/A.I. duPont Hospital for Children in Wilmington, DE with achondroplasia and T21 who underwent an initial polysomnogram (PSG) between 2015 and 2020. We compared sleep architecture parameters between the groups including sleep efficiency, total sleep time (TST), sleep latency, arousal index and concentration of N3 and REM sleep. Results In patients with achondroplasia (n=49, mean age 5.8 months and 63.3% male), 12% reported restless sleep. PSG data revealed TST of 392 minutes, mean sleep efficiency of 82%, mean sleep latency of 9.4 min, mean arousal index of 40, 22% REM sleep and 32% N3 sleep. In the patients with T21 (n=32, mean age 17.8 months and 50% male), 59% reported restless sleep. PSG data revealed TST of 393 minutes, mean sleep efficiency of 82%, mean sleep latency of 14 minutes, arousal index of 35, 15% REM sleep and 40% N3 sleep. The differences in REM and N3 sleep between the two groups were statistically significant (p-values of 0.001 and 0.04, respectively), but the differences in arousal index, TST and sleep efficiency were not. Conclusion Our study showed that children with T21 subjectively noted more restless sleep compared to patients with achondroplasia although TST and sleep efficiency were similar. Patients with achondroplasia had a higher arousal index that was not statistically significant. Children with achondroplasia had a shorter sleep latency and more robust REM concentration, likely due to their younger age. There was a higher concentration of N3 sleep in patients with T21. This is likely due to the decrease in REM concentration. In conclusion, it is important to establish expected sleep parameters in patients with achondroplasia and T21 to maximize sleep quality and mitigate negative neurocognitive effects of poor sleep. Support (if any):

Download Full-text

Protein and Omega-3 Polyunsaturated Fatty Acid Supplementation for 16 Weeks Improves Sleep and Mood States in Postmenopausal Women

Current Developments in Nutrition ◽

10.1093/cdn/nzaa040_009 ◽

2020 ◽

Vol 4 (Supplement_2) ◽

pp. 9-9

Author(s):

Jamie Baum ◽

Aubree Hawley ◽

Caroline Baughn ◽

Sam Walker ◽

Angela Tacinelli ◽

...

Keyword(s):

Body Composition ◽

Sleep Quality ◽

Postmenopausal Women ◽

Dietary Intervention ◽

Sleep Time ◽

Protein Isolate ◽

Mood States ◽

Current Evidence ◽

Omega 3 ◽

Wrist Actigraphy

Abstract Objectives Body composition shifts as we age, resulting in loss of skeletal muscle mass with an increase in fat mass, which is linked to disruptions in sleep-wake rhythms and mood disturbance. Current evidence suggests protein and omega-3 polyunsaturated fatty acids (O3FA) individually augment sleep quality and attenuate depression, but a concomitant effect is yet to be determined. The objective of this study was to determine the effect of protein and O3FA supplementation on regulation of sleep and mood states in postmenopausal women. Methods Overweight, postmenopausal women (60.6 ± 9.0 years; BMI: 28.1 ± 6.9) participated in this randomized, controlled, single-blinded, 16 wk dietary intervention. Participants were allocated to 1 of 5 groups: 1) control, no INT (n = 6); 2) whey protein isolate (PRO; 25 g/d; n = 4); 3) O3FA (DHA/EPA; 4.3 g/d; n = 10); 4) PRO + soy bean oil (4.3 g/d) placebo (n = 6), and 5) PRO + O3FA (n = 8). Sleep (via Pittsburgh Sleep Quality Index Global Sleeping Score; PSQI GSS) and total mood disturbances; (TMD; via Profile of Mood States (POMS)) including six affect states of depression, fatigue, anger, tension, confusion, and vigor subscales were assessed at 0, 4, 8, 12, and 16 wks. Sleep was measured at 0, 8, and 16 wk via wrist Actigraphy. Body composition was measured via DXA at 0 and 16 wk. Data were analyzed using two-way ANOVA to assess the relationship between diet, sleep, and mood states over time. Results Overall, all interventions improved PSQI GSS (P < 0.05) by 16 wks. There was a trend for all interventions to improve sleep efficiency (P = 0.06), with no effect on total sleep time. All interventions improved TMD (P < 0.05) and vigor (P < 0.001), with a trend on depression (P = 0.06). PRO, O3FA, and O3FA + PRO significantly improved vigor at 12-wks (P < 0.01). PRO alone significantly improved vigor at 16 wk (P < 0.001) compared to CON. There was no significant effect of intervention on body composition. However, PRO, O3FA, and PRO + O3FA had a positive (564.7 ± 681.4 g) and the CON had a negative (−171.0 ± 991.6) net change of total lean mass at 16 wks. Conclusions This pilot study suggests that PRO, O3FA, and PRO + O3FA have potential to improve sleep and mood in overweight, postmenopausal women. Additional research is needed to determine the long-term individual and concomitant effect of PRO and O3FA on sleep and mood states. NCT0303041. Funding Sources Arkansas Biosciences Institute.

Download Full-text